High Cancer Drug Prices in the United States: Reasons and Proposed Solutions

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

(2013)   BLOOD

Market spiral pricing of cancer drugs

(2013) Donald W . Light et al.   CANCER

Australia’s ‘Fourth Hurdle’ Drug Review Comparing Costs And Benefits Holds Lessons For The United States

(2013) Ruth Lopert et al.   HEALTH AFFAIRS

Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

(2013) Stacie B. Dusetzina et al.   JOURNAL OF CLINICAL ONCOLOGY

Big Pharma and Social Responsibility — The Access to Medicine Index

(2013) Hans V. Hogerzeil   NEW ENGLAND JOURNAL OF MEDICINE

Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated With New Cancer Drugs

(2010) Scott R. Berry et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing

(2009) Bruce E. Hillner et al.   JOURNAL OF CLINICAL ONCOLOGY